Home
News
Create
Screeners
Insights
Jenburkt Pharmaceuticals
1,202.
80
-13.95
(-1.15%)
Market Cap
₹525.50 Cr
PE Ratio
15.92
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.15%
1M
+14.60%
6M
+20.79%
1Y
-7.83%
5Y
+198.39%
View Company Insights
Latest news about Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026
Oct 28, 2025
Jenburkt Pharmaceuticals Limited announced strong Q2 FY2026 results. Revenue from operations increased by 10.5% to Rs 4,555.70 lacs, while profit after tax grew by 11.3% to Rs 1,133.20 lacs compared to Q2 FY2025. Total income rose by 10.6% to Rs 4,763.66 lacs. For the half-year ended September 30, 2025, total revenue reached Rs 8,108.40 lacs, a 10% increase from the previous year. The company continues to focus exclusively on the pharmaceuticals segment. The Board of Directors approved these unaudited financial results on October 28, 2025, following a limited audit review by D.R. Mehta & Associates.
Jenburkt Pharmaceuticals Reports Strong Q4 Results, Announces Dividend
May 20, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation